Bayer drug approved for secondary stroke
A new, small molecule drug from Bayer AG was approved by the US Food and Drug Administration on 9 November to reduce the risk of secondary stroke in patients who have already experienced a disorder. The drug, Sunharbo (asundexian) inhibits factor XIa – an enzyme that plays a key role in blood clotting. According to Bayer, Sunharbo is the first drug of its kind to be approved for patients. When given in combination with an antiplatelet therapy, it has been shown to reduce stroke risk in two specific instances.
